Literature DB >> 1527521

The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia.

A Y Deutch1.   

Abstract

A recent hypothesis of the pathogenesis of schizophrenia posits a developmentally-specific dysfunction of the dopaminergic innervation of the prefrontal cortex (PFC; Weinberger, 1987; Berman and Weinberger, 1990). It has been difficult to reconcile this hypothesis with the observation that all clinically effective antipsychotic drugs used for the treatment of schizophrenia block dopamine D2 receptors (see Deutch et al., 1991a). A resolution between the suggestion of functional dopamine (DA) "depletion" in the PFC and enhanced subcortical DA function was offered by studies of Carter, Pycock, and associates (Carter and Pycock, 1980; Pycock et al., 1980a, b). These investigators reported that depletion of DA in the rat PFC enhanced DA utilization in subcortical sites such as the nucleus accumbens septi (NAS) and striatum. Thus, a functional deficit in DA neurotransmission in the PFC would increase subcortical DA turnover, and the D2 receptor blockade induced by antipsychotic drugs would counteract the increase in dopaminergic tone in subcortical sites. This hypothesis has been particularly influential because it incorporates both an explanation for negative symptoms, which are thought to reflect cortical dysfunction (a derangement in DA transmission in the PFC), and the efficacy of antipsychotic drugs in the treatment of positive symptoms (arising from increases in subcortical DA tone). As attractive as this hypothesis has been, the physiological underpinnings that subserve such system interactions have remained elusive. Pycock, Carter, and colleagues (Carter and Pycock, 1980; Pycock et al., 1980a, b) reported that 6-hydroxydopamine (6-OHDA) lesions of the PFC increase DA levels and DA turnover in the striatum; certain aspects of their findings have been confirmed (Martin-Iversen et al., 1986; Leccese and Lyness, 1987; Haroutounian et al., 1988). However, other groups have been unable to confirm either the biochemical or behavioral findings of Pycock and associates (Joyce et al., 1983; Oades et al., 1986; Deutch et al., 1990). Moreover, Pycock and colleagues did not observe consistent effects of PFC DA deafferentation on various indices of subcortical DA function (Carter and Pycock, 1980; Pycock et al., 1980a, b). In light of the importance that such DA system interactions may have in the pathogenesis of schizophrenia, we have reinvestigated the effects of cortical DA lesions on subcortical DA function.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1527521     DOI: 10.1007/978-3-7091-9211-5_5

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  38 in total

Review 1.  Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease.

Authors:  Michel Cyr; Frederic Calon; Marc Morissette; Thérèse Di Paolo
Journal:  J Psychiatry Neurosci       Date:  2002-01       Impact factor: 6.186

Review 2.  Opponency revisited: competition and cooperation between dopamine and serotonin.

Authors:  Y-Lan Boureau; Peter Dayan
Journal:  Neuropsychopharmacology       Date:  2010-09-29       Impact factor: 7.853

3.  Modulation of basolateral amygdala neuronal firing and afferent drive by dopamine receptor activation in vivo.

Authors:  J A Rosenkranz; A A Grace
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

4.  Dopamine terminals in the rat prefrontal cortex synapse on pyramidal cells that project to the nucleus accumbens.

Authors:  D B Carr; P O'Donnell; J P Card; S R Sesack
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

5.  Interregional cerebral metabolic associativity during a continuous performance task (Part I): healthy adults.

Authors:  Mark W Willis; Brenda E Benson; Terence A Ketter; Tim A Kimbrell; Mark S George; Andrew M Speer; Peter Herscovitch; Robert M Post
Journal:  Psychiatry Res       Date:  2008-09-17       Impact factor: 3.222

6.  Phencyclidine increases forebrain monoamine metabolism in rats and monkeys: modulation by the isomers of HA966.

Authors:  J D Jentsch; J D Elsworth; D E Redmond; R H Roth
Journal:  J Neurosci       Date:  1997-03-01       Impact factor: 6.167

Review 7.  Natural rewards, neuroplasticity, and non-drug addictions.

Authors:  Christopher M Olsen
Journal:  Neuropharmacology       Date:  2011-04-01       Impact factor: 5.250

Review 8.  The effects of stress on central dopaminergic neurons: possible clinical implications.

Authors:  J M Finlay; M J Zigmond
Journal:  Neurochem Res       Date:  1997-11       Impact factor: 3.996

Review 9.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

10.  Dissociable effects of noradrenaline, dopamine, and serotonin uptake blockade on stop task performance in rats.

Authors:  Andrea Bari; Dawn M Eagle; Adam C Mar; Emma S J Robinson; Trevor W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2009-04-30       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.